Compare HCAT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | CDXS |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Major Chemicals |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.7M | 154.4M |
| IPO Year | 2019 | 2008 |
| Metric | HCAT | CDXS |
|---|---|---|
| Price | $1.46 | $1.08 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $1.77 | ★ $6.14 |
| AVG Volume (30 Days) | 393.6K | ★ 846.3K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,136,000.00 | $138,590,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | N/A | $18.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.48 | ★ 32.30 |
| 52 Week Low | $0.96 | $0.96 |
| 52 Week High | $3.36 | $2.98 |
| Indicator | HCAT | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 36.20 |
| Support Level | $1.04 | $0.96 |
| Resistance Level | $1.84 | $1.24 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 13.10 | 23.53 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.